Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund

Nov 12, 2026, 3:13 PM

Read Full Article → Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund

Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund

Translate article text

Choose a language and wait for the translated text.

Pfizer has an extensive clinical programme for berobenatide, acquired via its $10bn takeover of Metsera.

Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund | PharmaVoice